A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED AND OPEN-LABEL ACTIVE-CONTROLLED, PARALLEL-GROUP, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF JNJ-64565111 IN NON-DIABETIC SEVERELY OBESE SUBJECTS

Intervention/treatment:
EFINOPEGDUTIDE (JNJ-64565111)
Medical condition:
OBESITY
Protocol code:
64565111OBE2001
Control number:
213980
Status:
Closed
Approved:
March 23, 2018
Date Completed:
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT03486392
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Senior Director Clinical Leader
Organization
Janssen Research & Development, LLC
Phone:
844-434-4210
Sponsor
JANSSEN INC

Locations

Ontario

Canadian Phase Onward
Toronto, Ontario, M3J 2C5
Dr. Anil K Gupta Medicine Professional Corporation
Toronto, Ontario, M9V 4B4
Joanne F. Liutkus Medicine Professional Corporation
Cambridge, Ontario, N1R 7L6
Manna Research
Toronto, Ontario, M9W 4L6

Quebec

Clinique des Maladies Lipidiques de Québec
Québec, Quebec, G1V 4W2
Manna Research
Lévis, Quebec, G6W 0M5
Manna Research
Pointe-Claire, Quebec, H9R 4S3

Results

See the results from the trial NCT03486392. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?